Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,321–1,330 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1321

    Medicine slug
    rifabutin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 16 to 69 hours

      Numeric value
      16
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:754d2d7f-f0db-4f89-8fcd-5e2ff52d5030 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25a60937-cbbe-4a50-994f-2ce15203f589 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10fb5949-5572-47bd-aaf0-018d9978cad8 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd6062e2-17c8-48f4-a1fe-69ebe410f583 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2026b67-4755-4236-96b6-a6b5e7399707 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df7d4103-42e4-4e4f-e053-2a95a90a8ce8 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:baf8ec98-bd0c-4b87-a7ee-813335431b89 (opens source in a new tab)

        Rifabutin label

        Version not recorded · Effective date not recorded

        Rifabutin was slowly eliminated from plasma in seven healthy adult volunteers, presumably because of distribution-limited elimination, with a mean terminal half-life of 45 (±17) hours (range: 16 to 69 hours).

  2. Projected row 1322

    Medicine slug
    rifampin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    14
    Source count
    14
    Agreement rate
    0.785714
    Recorded readings

    1. 3.35±0.66 hours

      Numeric value
      3.35
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b389b1a3-672f-47e3-916c-4a9c044b211b (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28109dee-3e5e-492b-b7d9-9ba46c0b5324 (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f3534c1-95e4-4bdd-b044-9026e4addf0c (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cb75e95-d165-4580-9340-42d7a9fd546e (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c39ee75-ae96-456d-bf47-16d49865345e (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b56004f0-f23d-47f6-80c7-39884fccbccc (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d53b6998-6e3b-4c6f-8465-2af6897d1efe (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50f706f9-5003-4e15-bece-85b6213b1f5c (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 ± 0.66 hours after a 600 mg oral dose, with increases up to 5.08 ± 2.45 hours reported after a 900 mg dose.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0391f1e1-70d4-4b15-8b58-055bb6a385b8 (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:410a314f-83bf-d9b3-e063-6294a90a872c (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:036ab68e-5085-4edc-bd83-784b43d64eab (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        In healthy adults, the mean biological half-life of rifampin in serum averages 3.35±0.66 hours after a 600 mg oral dose, with increases up to 5.08±2.45 hours reported after a 900 mg dose.

    2. 1.04 to 3.81 hours

      Numeric value
      1.04
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1f9f1e2-dfc0-4d31-a13b-b656d897b791 (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8be91604-d7cd-4f2b-997d-e3364e4092e5 (opens source in a new tab)

        Rifampin label

        Version not recorded · Effective date not recorded

        The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated.

  3. Projected row 1323

    Medicine slug
    rifapentine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 70.2 ± 9.1 L

      Numeric value
      70.2
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f95d726e-5a09-48dd-b719-e4400fb91c8f (opens source in a new tab)

        Rifapentine label

        Version not recorded · Effective date not recorded

        Distribution In a population pharmacokinetic analysis in 351 tuberculosis patients who received 600 mg rifapentine tablets in combination with isoniazid, pyrazinamide and ethambutol, the estimated apparent volume of distribution was 70.2 ± 9.1 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a64fb70-b85e-43d9-8bcd-7e893f568ae1 (opens source in a new tab)

        Rifapentine label

        Version not recorded · Effective date not recorded

        Distribution In a population pharmacokinetic analysis in 351 tuberculosis patients who received 600 mg PRIFTIN in combination with isoniazid, pyrazinamide and ethambutol, the estimated apparent volume of distribution was 70.2 ± 9.1 L.

  4. Projected row 1324

    Medicine slug
    rifaximin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 5.6 hours

      Numeric value
      5.6
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5e8e2fd-7087-4b78-9181-cc259c0be2f1 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of rifaximin in healthy subjects at steady-state was 5.6 hours and was 6 hours in IBS-D patients.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7afafa63-3236-4212-9589-045db6b01c0b (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of rifaximin in healthy subjects at steady-state was 5.6 hours and was 6 hours in IBS-D patients.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f73acb74-e930-4414-81e9-d2a01db36e30 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of rifaximin in healthy subjects at steady-state was 5.6 hours and was 6 hours in IBS-D patients.

  5. Projected row 1325

    Medicine slug
    rifaximin
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 67.5%

      Numeric value
      67.5
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5e8e2fd-7087-4b78-9181-cc259c0be2f1 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        In vivo , the mean protein binding ratio was 67.5% in healthy subjects and 62% in patients with hepatic impairment when XIFAXAN was administered.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7afafa63-3236-4212-9589-045db6b01c0b (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        In vivo , the mean protein binding ratio was 67.5% in healthy subjects and 62% in patients with hepatic impairment when XIFAXAN was administered.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f73acb74-e930-4414-81e9-d2a01db36e30 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        In vivo , the mean protein binding ratio was 67.5% in healthy subjects and 62% in patients with hepatic impairment when XIFAXAN was administered.

  6. Projected row 1326

    Medicine slug
    rifaximin
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5e8e2fd-7087-4b78-9181-cc259c0be2f1 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Irritable Bowel Syndrome with Diarrhea In patients with irritable bowel syndrome with diarrhea (IBS-D) treated with XIFAXAN 550 mg three times a day for 14 days, the median T max was 1 hour and mean C max and AUC were generally comparable with those in healthy subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7afafa63-3236-4212-9589-045db6b01c0b (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Irritable Bowel Syndrome with Diarrhea In patients with irritable bowel syndrome with diarrhea (IBS-D) treated with XIFAXAN 550 mg three times a day for 14 days, the median Tmax was 1 hour and mean Cmax and AUC were generally comparable with those in healthy subjects.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f73acb74-e930-4414-81e9-d2a01db36e30 (opens source in a new tab)

        Rifaximin label

        Version not recorded · Effective date not recorded

        Irritable Bowel Syndrome with Diarrhea In patients with irritable bowel syndrome with diarrhea (IBS-D) treated with XIFAXAN 550 mg three times a day for 14 days, the median T max was 1 hour and mean C max and AUC were generally comparable with those in healthy subjects.

  7. Projected row 1327

    Medicine slug
    rilpivirine
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 50 hours

      Numeric value
      50
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03880372-2c68-45c6-a53a-f420c49541d6 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        Elimination The terminal elimination half-life of rilpivirine is approximately 50 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb109de9-d88d-4405-8dd6-d458cbc387d1 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        Elimination The terminal elimination half-life of rilpivirine is approximately 50 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dadbf50d-6b7d-4fb5-bd9f-7769b048e764 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        Elimination The terminal elimination half-life of rilpivirine is approximately 50 hours.

  8. Projected row 1328

    Medicine slug
    rilpivirine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 99%

      Numeric value
      99
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03880372-2c68-45c6-a53a-f420c49541d6 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        The protein binding of rilpivirine was similar (>99%) during the second trimester, third trimester, and postpartum.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb109de9-d88d-4405-8dd6-d458cbc387d1 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        The protein binding of rilpivirine was similar (>99%) during the second trimester, third trimester, and postpartum.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dadbf50d-6b7d-4fb5-bd9f-7769b048e764 (opens source in a new tab)

        Rilpivirine label

        Version not recorded · Effective date not recorded

        The protein binding of rilpivirine was similar (>99%) during the second trimester, third trimester, and postpartum.

  9. Projected row 1329

    Medicine slug
    riluzole
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 60%

      Numeric value
      60
      Unit
      %
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d68f19-4208-109e-e053-2991aa0ac857 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        Absorption Bioavailability (oral) Approximately 60% Dose Proportionality Linear over a dose range of 25 mg to 100 mg every 12 hours (1/2 to 2 times the recommended dosage) Food effect Information specific to TIGLUTIK AUC ↓ 9% and Cmax ↓ 55% (high fat meal) Time to peak plasma concentration (median) 0.8 hours Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination E
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c851be4-f0d0-4b24-baf9-427ddfc6f7b0 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        Pharmacokinetic Parameters of Riluzole Absorption Bioavailability (oral) Approximately 60% Dose Proportionality Linear over a dose range of 25 mg to 100 mg every 12 hours (1/2 to 2 times the recommended dosage) Food effect AUC ↓ 20% and C max ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life 12 hours (CV=35%) The hi
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccead445-970c-46a1-9532-2848cc2aa3b6 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        Pharmacokinetic Parameters of Riluzole Absorption Bioavailability (oral) Approximately 60% Dose Proportionality Linear over a dose range of 25 mg to 100 mg every 12 hours (1/2 to 2 times the recommended dosage) Food effect AUC ↓ 20% and Cmax ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life 12 hours (CV=35%) The hig
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1ce57e8-d3fe-422c-8724-3101c258898a (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        Pharmacokinetic Parameters of Riluzole Absorption Bioavailability (oral) Approximately 60% Dose Proportionality Linear over a dose range of 25 mg to 100 mg every 12 hours (1/2 to 2 times the recommended dosage) Food effect AUC ↓ 20% and C max ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life • 12 hours (CV=35%) • Th
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd432c13-389e-46b3-8891-0cf1a58800ff (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        Pharmacokinetic Parameters of Riluzole A bsorption Bioavailability (oral) Approximately 60% Dose Proportionality Linear over a dose range of 25 mg to 100 mg every 12 hours (1/2 to 2 times the recommended dosage) Food effect AUC ↓ 20% and Cmax ↓ 45% (high fat meal) D i stribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) E li m i n ation Elimination half-life • 12 hours (CV=35

  10. Projected row 1330

    Medicine slug
    riluzole
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 12 hours

      Numeric value
      12
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d68f19-4208-109e-e053-2991aa0ac857 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        ↓ 9% and Cmax ↓ 55% (high fat meal) Time to peak plasma concentration (median) 0.8 hours Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life 12 hours (CV=35%) The high individual variability in the clearance of riluzole is potentially attributable to variability of CYP1A2.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c851be4-f0d0-4b24-baf9-427ddfc6f7b0 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        to 2 times the recommended dosage) Food effect AUC ↓ 20% and C max ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life 12 hours (CV=35%) The high interindividual variability in the clearance of riluzole is potentially attributable to variability of CYP1A2.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccead445-970c-46a1-9532-2848cc2aa3b6 (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        2 to 2 times the recommended dosage) Food effect AUC ↓ 20% and Cmax ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life 12 hours (CV=35%) The high interindividual variability in the clearance of riluzole is potentially attributable to variability of CYP1A2.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1ce57e8-d3fe-422c-8724-3101c258898a (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        to 2 times the recommended dosage) Food effect AUC ↓ 20% and C max ↓ 45% (high fat meal) Distribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) Elimination Elimination half-life • 12 hours (CV=35%) • The high interindividual variability in the clearance of riluzole is potentially attributable to variability of CYP1A2.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd432c13-389e-46b3-8891-0cf1a58800ff (opens source in a new tab)

        Riluzole label

        Version not recorded · Effective date not recorded

        imes the recommended dosage) Food effect AUC ↓ 20% and Cmax ↓ 45% (high fat meal) D i stribution Plasma Protein Binding 96% (Mainly to albumin and lipoproteins) E li m i n ation Elimination half-life • 12 hours (CV=35%) • The high interindividual variability in the clearance of riluzole is potentially attributable to variability of CYP1A2.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1320

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy